TY - JOUR
T1 - APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis
AU - Zee, Jarcy
AU - McNulty, Michelle T.
AU - Hodgin, Jeffrey B.
AU - Zhdanova, Olga
AU - Hingorani, Sangeeta
AU - Jefferson, Jonathan Ashley
AU - Gibson, Keisha L.
AU - Trachtman, Howard
AU - Fornoni, Alessia
AU - Dell, Katherine M.
AU - Reich, Heather N.
AU - Bagnasco, Serena
AU - Greenbaum, Larry A.
AU - Lafayette, Richard A.
AU - Gipson, Debbie S.
AU - Brown, Elizabeth
AU - Kretzler, Matthias
AU - Appel, Gerald
AU - Sambandam, Kamalanathan K.
AU - Tuttle, Katherine R.
AU - Chen, Dhruti
AU - Atkinson, Meredith A.
AU - Hogan, Marie C.
AU - Kaskel, Frederick J.
AU - Meyers, Kevin E.
AU - O’Toole, John
AU - Srivastava, Tarak
AU - Sethna, Christine B.
AU - Hladunewich, Michelle A.
AU - Lin, Jj
AU - Nast, Cynthia C.
AU - Derebail, Vimal K.
AU - Patel, Jiten
AU - Vento, Suzanne
AU - Holzman, Lawrence B.
AU - Athavale, Ambarish M.
AU - Adler, Sharon G.
AU - Lemley, Kevin V.
AU - Lieske, John C.
AU - Hogan, Jonathan J.
AU - Gadegbeku, Crystal A.
AU - Fervenza, Fernando C.
AU - Wang, Chia Shi
AU - Matar, Raed Bou
AU - Singer, Pamela
AU - Kopp, Jeffrey B.
AU - Barisoni, Laura
AU - Sampson, Matthew G.
N1 - Funding Information:
This study was supported by a grant from the National Institute of Diabetes, Digestive, and Kidney Diseases to MGS (NIDDK R01-DK108805). Support for JBK was provided by the NIDDK Intramural Research Program. The Nephrotic Syndrome Study Network Consortium (NEPTUNE), U54-DK-083912, is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through a collaboration between the Office of Rare Diseases Research, National Center for Advancing Translational Sciences and the National Institute of Diabetes, Digestive, and Kidney Diseases. Additional funding and/or programmatic support for this project has also been provided by the University of Michigan, the NephCure Kidney International and the Halpin Foundation.
Funding Information:
NEPTUNE Enrolling Centers Cleveland Clinic, Cleveland, OH: K Dell*, J Sedor**, M Schachere#, J Negrey# Children?s Hospital, Los Angeles, CA: K Lemley*, E Lim# Children?s Mercy Hospital, Kansas City, MO: T Srivastava*, A Garrett# Cohen Children?s Hospital, New Hyde Park, NY: C Sethna*, K Laurent # Columbia University, New York, NY: P Canetta*, A Pradhan# Emory University, Atlanta, GA: L Greenbaum*, C Wang**, C Kang# Harbor-University of California Los Angeles Medical Center: S Adler*, J LaPage# John H. Stroger Jr. Hospital of Cook County, Chicago, IL: A Athavale*, M Itteera Johns Hopkins Medicine, Baltimore, MD: M Atkinson*, S Boynton# Mayo Clinic, Rochester, MN: F Fervenza*, M Hogan**, J Lieske*, V Chernitskiy# Montefiore Medical Center, Bronx, NY: F Kaskel*, M Ross*, P Flynn# NIDDK Intramural, Bethesda MD: J Kopp*, J Blake# New York University Medical Center, New York, NY: H Trachtman*, O Zhdanova**, F Modersitzki#, S Vento# Stanford University, Stanford, CA: R Lafayette*, K Mehta# Temple University, Philadelphia, PA: C Gadegbeku*, S Quinn-Boyle# University Health Network Toronto: M Hladunewich**, H Reich**, P Ling#, M Romano# University of Miami, Miami, FL: A Fornoni*, C Bidot# University of Michigan, Ann Arbor, MI: M Kretzler*, D Gipson*, A Williams#, J LaVigne# University of North Carolina, Chapel Hill, NC: V Derebail*, K Gibson*, E Cole#, J Ormond-Foster# University of Pennsylvania, Philadelphia, PA: L Holzman*, K Meyers**, K Kallem#, A Swenson# University of Texas Southwestern, Dallas, TX: K Sambandam*, Z Wang#, M Rogers# University of Washington, Seattle, WA: A Jefferson*, S Hingorani**, K Tuttle**?, M Bray #, M Kelton#, A Cooper#? Wake Forest University Baptist Health, Winston-Salem, NC: JJ Lin*, Stefanie Baker# Data Analysis and Coordinating Center: M Kretzler, L Barisoni, J Bixler, H Desmond, S Eddy, D Fermin, C Gadegbeku, B Gillespie, D Gipson, L Holzman, V Kurtz, M Larkina, J Lavigne, S Li, S Li, CC Lienczewski, J Liu, T Mainieri, L Mariani, M Sampson, J Sedor, A Smith, A Williams, J Zee. Digital Pathology Committee: Carmen Avila-Casado (University Health Network, Toronto), Serena Bagnasco (Johns Hopkins University), Joseph Gaut (Washington University in St Louis), Stephen Hewitt (National Cancer Institute), Jeff Hodgin (University of Michigan), Kevin Lemley (Children?s Hospital of Los Angeles), Laura Mariani (University of Michigan), Matthew Palmer (University of Pennsylvania), Avi Rosenberg (Johns Hopkins University), Virginie Royal (University of Montreal), David Thomas (University of Miami), Jarcy Zee (University of Pennsylvania) Co-Chairs: Laura Barisoni (Duke University) and Cynthia Nast (Cedar Sinai).*Principal Investigator;**Co-investigator;#Study Coordinator?Providence Medical Research Center, Spokane, WA
Publisher Copyright:
© 2021, IPNA.
PY - 2021/9
Y1 - 2021/9
N2 - Background: The G1 and G2 alleles of apolipoprotein L1 (APOL1) are common in the Black population and associated with increased risk of focal segmental glomerulosclerosis (FSGS). The molecular mechanisms linking APOL1 risk variants with FSGS are not clearly understood, and APOL1’s natural absence in laboratory animals makes studying its pathobiology challenging. Methods: In a cohort of 90 Black patients with either FSGS or minimal change disease (MCD) enrolled in the Nephrotic Syndrome Study Network (58% pediatric onset), we used kidney biopsy traits as an intermediate outcome to help illuminate tissue-based consequences of APOL1 risk variants and expression. We tested associations between APOL1 risk alleles or glomerular APOL1 mRNA expression and 83 light- or electron-microscopy traits measuring structural and cellular kidney changes. Results: Under both recessive and dominant models in the FSGS patient subgroup (61%), APOL1 risk variants were significantly correlated (defined as FDR <0.1) with decreased global mesangial hypercellularity, decreased condensation of cytoskeleton, and increased tubular microcysts. No significant correlations were detected in MCD cohort. Independent of risk alleles, glomerular APOL1 expression in FSGS patients was not correlated with morphologic features. Conclusions: While APOL1-associated FSGS is associated with two risk alleles, both one and two risk alleles are associated with cellular/tissue changes in this study of FSGS patients. Our lack of discovery of a large group of tissue differences in FSGS and no significant difference in MCD may be due to the lack of power but also supports investigating whether machine learning methods may more sensitively detect APOL1-associated changes. [Figure not available: see fulltext.]
AB - Background: The G1 and G2 alleles of apolipoprotein L1 (APOL1) are common in the Black population and associated with increased risk of focal segmental glomerulosclerosis (FSGS). The molecular mechanisms linking APOL1 risk variants with FSGS are not clearly understood, and APOL1’s natural absence in laboratory animals makes studying its pathobiology challenging. Methods: In a cohort of 90 Black patients with either FSGS or minimal change disease (MCD) enrolled in the Nephrotic Syndrome Study Network (58% pediatric onset), we used kidney biopsy traits as an intermediate outcome to help illuminate tissue-based consequences of APOL1 risk variants and expression. We tested associations between APOL1 risk alleles or glomerular APOL1 mRNA expression and 83 light- or electron-microscopy traits measuring structural and cellular kidney changes. Results: Under both recessive and dominant models in the FSGS patient subgroup (61%), APOL1 risk variants were significantly correlated (defined as FDR <0.1) with decreased global mesangial hypercellularity, decreased condensation of cytoskeleton, and increased tubular microcysts. No significant correlations were detected in MCD cohort. Independent of risk alleles, glomerular APOL1 expression in FSGS patients was not correlated with morphologic features. Conclusions: While APOL1-associated FSGS is associated with two risk alleles, both one and two risk alleles are associated with cellular/tissue changes in this study of FSGS patients. Our lack of discovery of a large group of tissue differences in FSGS and no significant difference in MCD may be due to the lack of power but also supports investigating whether machine learning methods may more sensitively detect APOL1-associated changes. [Figure not available: see fulltext.]
KW - APOL1
KW - Focal segmental glomerulosclerosis
KW - Minimal change disease
KW - Morphology
KW - Pediatric
UR - http://www.scopus.com/inward/record.url?scp=85101805898&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101805898&partnerID=8YFLogxK
U2 - 10.1007/s00467-021-04990-4
DO - 10.1007/s00467-021-04990-4
M3 - Article
C2 - 33646395
AN - SCOPUS:85101805898
SN - 0931-041X
VL - 36
SP - 2747
EP - 2757
JO - Pediatric Nephrology
JF - Pediatric Nephrology
IS - 9
ER -